Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance therapy for peripheral T-cell lymphoma
ChiCTR1900025028Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tucidinostat in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR1900025028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025028.